Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
18.07. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
03.07. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Azitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome | 152 | PR Newswire | Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site
Trial is 50% enrolled... ► Artikel lesen | |
14.05. | Azitra GAAP EPS of -$0.23 | 1 | Seeking Alpha | ||
AZITRA Aktie jetzt für 0€ handeln | |||||
13.05. | Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates | 135 | PR Newswire | BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
13.05. | Azitra, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
13.05. | Azitra, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
02.05. | Azitra, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
29.04. | Azitra, Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
24.04. | Azitra, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
24.04. | Azitra secures funding deal for dermatology treatments | 1 | Investing.com | ||
24.04. | Azitra sichert Finanzierungsvereinbarung für Dermatologie-Behandlungen | 1 | Investing.com Deutsch | ||
26.02. | Maxim Group cuts Azitra stock price target to $2 from $3, retains Buy rating | 6 | Investing.com | ||
25.02. | Azitra reports FY results | 2 | Seeking Alpha | ||
24.02. | Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates | 174 | PR Newswire | BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
24.02. | Azitra, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.02. | Azitra, Inc. - 8-K, Current Report | - | SEC Filings | ||
12.11.24 | Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates | 168 | PR Newswire | BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
29.10.24 | Azitra, Inc.: Azitra to Present at BIO-Europe 2024 | 414 | Business Wire | Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the Company will present at... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
BEAM THERAPEUTICS | 17,620 | -1,34 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
JANUX THERAPEUTICS | 22,830 | +1,11 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
EVOTEC | 6,778 | +1,35 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 46,240 | -2,69 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 32,150 | -2,90 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
COGENT BIOSCIENCES | 10,960 | +0,83 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
ARS PHARMACEUTICALS | 17,500 | -0,85 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
ADMA BIOLOGICS | 16,525 | -1,34 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DAY ONE BIOPHARMACEUTICALS | 6,100 | +1,16 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
ARCELLX | 70,53 | -0,87 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
AMYLYX PHARMACEUTICALS | 7,640 | -2,55 % | Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline | ||
SUMMIT THERAPEUTICS | 28,675 | +2,16 % | Summit Therapeutics: Ivonescimab zeigt überlegenes progressionsfreies Überleben gegenüber Pembrolizumab | ||
TANGO THERAPEUTICS | 6,610 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | - First patient dosed in combination trial of TNG462 and Revolution Medicines RAS(ON) inhibitors - - First patient dosed in Phase 1/2 trial with TNG456, a brain-penetrant MTA-cooperative PRMT5... ► Artikel lesen |